Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Inclusion Criteria: * Age ≥ 18 * Documented HIV-1 infection, hepatitis B or C co-infection is allowed * Plasma viral load at screening visit below 50 copies per mL for at least 6 months * Patient with severe liver failure (Meld Score ≥ 15 and/or refractory ascites and/or haemorrhage of digestive tract and/or hepatic encephalopathy) for taking part into period 1 * Patient eligible for the liver transplant waiting list or immediate post transplantation for taking part into period 2 * Abstinence from alcohol intake for at least 6 months (WHO norm) * Withdrawal from intravenous drug use for at least 6 months (methadone substitution is permitted) * No ongoing class C opportunistic infection (1993 CDC classification) * Patient whose clinical and immunovirological condition allows triple therapy with raltegravir + 2 NRTI or raltegravir + NRTI + enfuvirtide * Patient whose HIV population, according to cumulative genotypes carried out on viral RNA together with treatment history (if available and interpreted as per the ANRS-AC11 algorithm version no.19) does not present a profile of mutations associated with resistance to raltegravir and is sensitive to at least two fully active\* agents selected among nucleoside/nucleotide reverse transcriptase analogs NRTI (abacavir, lamivudine, emtricitabine, tenofovir) or enfuvirtide \*An ARV agent is considered to be fully active if the cumulative genotypes do not show any mutation associated with resistance or any mutation associated with "p…